265 related articles for article (PubMed ID: 27494872)
41. Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis.
Abdi J; Rastgoo N; Li L; Chen W; Chang H
J Hematol Oncol; 2017 Oct; 10(1):169. PubMed ID: 29073933
[TBL] [Abstract][Full Text] [Related]
42. MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance.
Desantis V; Saltarella I; Lamanuzzi A; Melaccio A; Solimando AG; Mariggiò MA; Racanelli V; Paradiso A; Vacca A; Frassanito MA
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349317
[TBL] [Abstract][Full Text] [Related]
43. microRNA regulation of cell viability and drug sensitivity in lung cancer.
Du L; Pertsemlidis A
Expert Opin Biol Ther; 2012 Sep; 12(9):1221-39. PubMed ID: 22731874
[TBL] [Abstract][Full Text] [Related]
44. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.
Du J; Liu S; He J; Liu X; Qu Y; Yan W; Fan J; Li R; Xi H; Fu W; Zhang C; Yang J; Hou J
Oncotarget; 2015 Jun; 6(17):14993-5007. PubMed ID: 25915427
[TBL] [Abstract][Full Text] [Related]
45. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice.
Giovannetti E; Erozenci A; Smit J; Danesi R; Peters GJ
Crit Rev Oncol Hematol; 2012 Feb; 81(2):103-22. PubMed ID: 21546262
[TBL] [Abstract][Full Text] [Related]
46. MiRNAs-mediated cisplatin resistance in breast cancer.
Chen X; Lu P; Wu Y; Wang DD; Zhou S; Yang SJ; Shen HY; Zhang XH; Zhao JH; Tang JH
Tumour Biol; 2016 Oct; 37(10):12905-12913. PubMed ID: 27448297
[TBL] [Abstract][Full Text] [Related]
47. MicroRNA-21 and multiple myeloma: small molecule and big function.
Ma J; Liu S; Wang Y
Med Oncol; 2014 Aug; 31(8):94. PubMed ID: 24981236
[TBL] [Abstract][Full Text] [Related]
48. From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario.
Rossi M; Amodio N; Di Martino MT; Caracciolo D; Tagliaferri P; Tassone P
Curr Drug Targets; 2013 Sep; 14(10):1144-9. PubMed ID: 23834146
[TBL] [Abstract][Full Text] [Related]
49. miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients.
Troppan K; Wenzl K; Pichler M; Pursche B; Schwarzenbacher D; Feichtinger J; Thallinger GG; Beham-Schmid C; Neumeister P; Deutsch A
Int J Mol Sci; 2015 Aug; 16(8):18077-95. PubMed ID: 26251897
[TBL] [Abstract][Full Text] [Related]
50. miRNAs mediated drug resistance in hematological malignancies.
Peixoto da Silva S; Caires HR; Bergantim R; Guimarães JE; Vasconcelos MH
Semin Cancer Biol; 2022 Aug; 83():283-302. PubMed ID: 33757848
[TBL] [Abstract][Full Text] [Related]
51. MicroRNAs in the pathobiology of multiple myeloma.
Lionetti M; Agnelli L; Lombardi L; Tassone P; Neri A
Curr Cancer Drug Targets; 2012 Sep; 12(7):823-37. PubMed ID: 22671930
[TBL] [Abstract][Full Text] [Related]
52. Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs.
Mao L; Li J; Chen WX; Cai YQ; Yu DD; Zhong SL; Zhao JH; Zhou JW; Tang JH
Tumour Biol; 2016 Apr; 37(4):5247-56. PubMed ID: 26555545
[TBL] [Abstract][Full Text] [Related]
53. Curcumin as a MicroRNA Regulator in Cancer: A Review.
Momtazi AA; Shahabipour F; Khatibi S; Johnston TP; Pirro M; Sahebkar A
Rev Physiol Biochem Pharmacol; 2016; 171():1-38. PubMed ID: 27457236
[TBL] [Abstract][Full Text] [Related]
54. Drug resistance-related microRNAs in hematological malignancies: translating basic evidence into therapeutic strategies.
Xie L; Jing R; Qi J; Lin Z; Ju S
Blood Rev; 2015 Jan; 29(1):33-44. PubMed ID: 25263425
[TBL] [Abstract][Full Text] [Related]
55. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
Zhu W; Xu H; Zhu D; Zhi H; Wang T; Wang J; Jiang B; Shu Y; Liu P
Cancer Chemother Pharmacol; 2012 Mar; 69(3):723-31. PubMed ID: 21993663
[TBL] [Abstract][Full Text] [Related]
56. Role of microRNAs in drug-resistant ovarian cancer cells.
Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
[TBL] [Abstract][Full Text] [Related]
57. MicroRNA-Based Combinatorial Cancer Therapy: Effects of MicroRNAs on the Efficacy of Anti-Cancer Therapies.
Seo HA; Moeng S; Sim S; Kuh HJ; Choi SY; Park JK
Cells; 2019 Dec; 9(1):. PubMed ID: 31861937
[TBL] [Abstract][Full Text] [Related]
58. The potential role of miRNAs in multiple myeloma therapy.
Caracciolo D; Montesano M; Altomare E; Scionti F; Di Martino MT; Tagliaferri P; Tassone P
Expert Rev Hematol; 2018 Oct; 11(10):793-803. PubMed ID: 30148649
[TBL] [Abstract][Full Text] [Related]
59. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
[TBL] [Abstract][Full Text] [Related]
60. Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines.
Zhuo L; Liu J; Wang B; Gao M; Huang A
Oncol Rep; 2013 Feb; 29(2):555-62. PubMed ID: 23229111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
